JP6858131B2 - 自閉症を治療するための組成物及び方法 - Google Patents

自閉症を治療するための組成物及び方法 Download PDF

Info

Publication number
JP6858131B2
JP6858131B2 JP2017554262A JP2017554262A JP6858131B2 JP 6858131 B2 JP6858131 B2 JP 6858131B2 JP 2017554262 A JP2017554262 A JP 2017554262A JP 2017554262 A JP2017554262 A JP 2017554262A JP 6858131 B2 JP6858131 B2 JP 6858131B2
Authority
JP
Japan
Prior art keywords
tyrosine
methyl
pharmaceutically acceptable
acceptable salt
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017554262A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018511639A (ja
JP2018511639A5 (enExample
Inventor
スティーブン・ホフマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/686,545 external-priority patent/US9308188B2/en
Priority claimed from US15/059,602 external-priority patent/US9763903B2/en
Application filed by Individual filed Critical Individual
Publication of JP2018511639A publication Critical patent/JP2018511639A/ja
Publication of JP2018511639A5 publication Critical patent/JP2018511639A5/ja
Application granted granted Critical
Publication of JP6858131B2 publication Critical patent/JP6858131B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
JP2017554262A 2015-04-14 2016-03-28 自閉症を治療するための組成物及び方法 Active JP6858131B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14/686,545 US9308188B2 (en) 2013-10-22 2015-04-14 Compositions and methods for treating intestinal hyperpermeability
US14/686,545 2015-04-14
US15/059,602 2016-03-03
US15/059,602 US9763903B2 (en) 2013-10-22 2016-03-03 Compositions and methods for treating intestinal hyperpermeability
PCT/US2016/024432 WO2016167944A2 (en) 2015-04-14 2016-03-28 Compositions and methods for treating intestinal hyperpermeability

Publications (3)

Publication Number Publication Date
JP2018511639A JP2018511639A (ja) 2018-04-26
JP2018511639A5 JP2018511639A5 (enExample) 2019-05-16
JP6858131B2 true JP6858131B2 (ja) 2021-04-14

Family

ID=57126753

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017554262A Active JP6858131B2 (ja) 2015-04-14 2016-03-28 自閉症を治療するための組成物及び方法

Country Status (12)

Country Link
EP (2) EP4438059A3 (enExample)
JP (1) JP6858131B2 (enExample)
KR (1) KR20180015126A (enExample)
CN (1) CN107835695B (enExample)
AU (1) AU2016247301A1 (enExample)
BR (1) BR112017022184A2 (enExample)
CA (1) CA2982442A1 (enExample)
EA (1) EA038339B1 (enExample)
IL (1) IL254963A0 (enExample)
MX (1) MX2017013176A (enExample)
PH (1) PH12017501864A1 (enExample)
WO (1) WO2016167944A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10813901B2 (en) 2013-10-22 2020-10-27 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
US10751313B2 (en) 2013-10-22 2020-08-25 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
JP2021530568A (ja) * 2018-07-19 2021-11-11 ヤモ・ファーマシューティカルズ・エルエルシー 自閉症を処置するための組成物および方法
WO2020018292A1 (en) * 2018-07-19 2020-01-23 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
KR102726917B1 (ko) 2019-02-01 2024-11-07 닥터레이몬드 랩(주) 자폐증의 예측방법
EP3968785A4 (en) 2019-05-14 2023-01-11 Tyme, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4165382A (en) * 1977-10-17 1979-08-21 Jose Pozuelo Method of pharmacologically treating schizophrenia with alpha-methyl-para-tyrosine
WO2001078704A2 (en) * 2000-04-13 2001-10-25 Evans William T Gaba substrate and the use thereof for treating cognitive and emotional disorders
WO2006039691A2 (en) * 2004-10-01 2006-04-13 The Research Foundation Of State University Of New York Morphine and morphine precursors
US9949923B2 (en) * 2011-03-15 2018-04-24 Optinose As Nasal delivery
PL220308B1 (pl) * 2011-06-03 2015-10-30 Kobel Buys Krystyna Zastosowanie klenbuterolu do leczenia objawów autyzmu dziecięcego oraz klenbuterol do zastosowania w leczeniu objawów autyzmu dziecięcego
KR20190109564A (ko) * 2012-01-03 2019-09-25 큐어마크, 엘엘씨 신경계 및 정신 장애의 행동 증상을 치료하는 방법
US20130183263A1 (en) * 2012-01-17 2013-07-18 Steven Hoffman Pharmaceutical compositions and methods
US9326962B2 (en) * 2013-10-22 2016-05-03 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US20150111878A1 (en) * 2013-10-22 2015-04-23 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability

Also Published As

Publication number Publication date
PH12017501864A1 (en) 2018-03-05
KR20180015126A (ko) 2018-02-12
IL254963A0 (en) 2017-12-31
EA038339B1 (ru) 2021-08-11
EP3283115C0 (en) 2024-06-12
WO2016167944A3 (en) 2017-08-10
JP2018511639A (ja) 2018-04-26
CN107835695B (zh) 2021-07-09
WO2016167944A8 (en) 2017-11-02
WO2016167944A2 (en) 2016-10-20
EP4438059A3 (en) 2025-01-01
EP4438059A2 (en) 2024-10-02
EP3283115B1 (en) 2024-06-12
CA2982442A1 (en) 2016-10-20
CN107835695A (zh) 2018-03-23
AU2016247301A1 (en) 2017-10-26
EA201792278A1 (ru) 2018-04-30
MX2017013176A (es) 2018-01-30
BR112017022184A2 (pt) 2018-07-03
EP3283115A2 (en) 2018-02-21

Similar Documents

Publication Publication Date Title
AU2020203101B9 (en) Tyrosine hydroxylase inhibitors for treating intestinal hyperpermeability
US9763903B2 (en) Compositions and methods for treating intestinal hyperpermeability
US10857118B2 (en) Compositions and methods for treating intestinal hyperpermeability
CN107835695B (zh) 用于治疗自闭症的组合物和方法
US20230310358A1 (en) Compositions And Methods For Treating Autism
US10751313B2 (en) Compositions and methods for treating autism
JP2021530569A (ja) 自閉症を処置するための組成物および方法
JP2021530568A (ja) 自閉症を処置するための組成物および方法
HK40116464A (en) Compositions and methods for treating intestinal hyperpermeability

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190320

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190320

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200414

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200611

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201012

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210108

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210222

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210323

R150 Certificate of patent or registration of utility model

Ref document number: 6858131

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250